Digital Therapeutic
Digital Therapeutic
Search
Slovenia
Serbia
Serbia
Latvia
Latvia
Lithuania
Lithuania
Bulgaria
Bulgaria
Israel
Israel
Kazakhstan
Kazakhstan
Bosnia and Herzegovina
Bosnia and Herzegovina
Survodutide (BI 456906): GLP1/GCGR agonist | MASH
Survodutide (BI 456906): GLP1/GCGR agonist | MASH
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
Duluth
Duluth
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Survodutide (BI 456906): GLP1/GCGR agonist | obesity
Pascal Haubert
Three months into an internship with us, Pascal Haubert talks about responsibility, learning, and mutual support.
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
Pradaxa US Litigation settlement
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
SPEVIGO CHMP positive opinion new indications
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®